Integrated Biochemical Manufacturing Platform
Phase 1 Business Summary
“Converting Brewery Waste into High-Value Biochemicals”
CONFIDENTIAL INVESTMENT MEMORANDUM
© 2028 Promecens Entosystems Private Limited / Shield Nutraceuticals, Inc.
Executive Summary | Phase 1 & 2
Guatemala BSF Biorefinery
Integrated Financial Overview
January 2028
Total Investment (Ph 1+2)
| Investment | Amount |
|---|---|
| Total Investment | $14.12M |
| Phase 1 (Y1) | $9.45M |
| Phase 2 (Y3) | $4.675M |
Year 5 Revenue
| Metric | Value |
|---|---|
| Revenue | $81.40M |
| Products | 11 Products |
| Revenue Mix | Phase 1 ($54.1M) + Phase 2 ($27.3M) |
5-Year ROI
| Metric | Value |
|---|---|
| ROI | 1,334% |
| Return Type | Cumulative Return |
| EBITDA | $202.45M Total EBITDA |
Payback Period
| Metric | Value |
|---|---|
| Payback | 8.3 Months |
| Status | Rapid capital recovery |
Revenue Mix (Year 5)
11 Revenue Streams
PHASE 1 CORE ($54.10M)
| Business Unit | Revenue |
|---|---|
| Melanin & Chitosan | $42.8M |
| Protein & Oil | $11.3M |
PHASE 2 EXPANSION ($27.30M)
| Business Unit | Revenue |
|---|---|
| Biochar & Mushrooms | $16.0M |
| Biochemicals (AMPs, Poly) | $11.3M |
| Performance Metric | Value |
|---|---|
| Avg. EBITDA Margin | 79.5% |
5-Year Integrated Revenue Trajectory
Revenue Categories
| Series |
|---|
| Total EBITDA ($M) |
| Phase 1 Revenue |
| Phase 2 Revenue |
Annual Revenue Timeline
| Year | Revenue Trend |
|---|---|
| Year 1 | Phase 1 Launch |
| Year 2 | Growth |
| Year 3 | Phase 2 Begins |
| Year 4 | Expansion |
| Year 5 | Full Capacity |
Chart Axis
| Y-Axis (Millions $) |
|---|
| $0M |
| $10M |
| $20M |
| $30M |
| $40M |
| $50M |
| $60M |
| $70M |
| $80M |
| $90M |
The Opportunity
Transforming Waste Liability into High-Value Assets
Current State
Input Source
| Input | Volume |
|---|---|
| Brewery Waste | 48,000 MT / Year |
Product Output
| Current Product | Market Position |
|---|---|
| Hog Feed | Low-value commodity |
Annual Revenue
| Metric | Value |
|---|---|
| Total Annual Revenue | $4.13M |
| Average Price | @ $86/MT |
Value Transformation
| Value Increase |
|---|
| 20× VALUE UPLIFT |
Future State
Input Source
| Input | Volume |
|---|---|
| Same Brewery Waste | 48,000 MT |
| Production Scope | Phase 1 + Phase 2 Expansion |
Product Output
| Output | Description |
|---|---|
| 12 High-Value Streams | Pharma, Agriculture, Food & Advanced Materials |
Financial Projection
| Metric | Value |
|---|---|
| Projected Annual Revenue (Year 5) | $84.60M |
| Revenue Growth | +2,000% Uplift |
Complete Product Portfolio
Year 5 Projection: 11 Revenue Streams
Total Annual Revenue: $81.40M
Revenue Mix
| Phase | Revenue |
|---|---|
| Phase 1 | $54.10M |
| Phase 2 | $27.30M |
| Total | $81.40M |
PHASE 1 — Core Biorefinery Products
| Product | Category | Revenue | Share |
|---|---|---|---|
| Melanin | Bioelectronics | $27.56M | 34% |
| Chitosan | Pharma Grade | $15.23M | 19% |
| Insect Oil | Lipids | $5.84M | 7% |
| Protein | Feed | $5.47M | 7% |
PHASE 2 — Expansion & Regenerative Agriculture
| Product | Application | Revenue |
|---|---|---|
| Biochar | Fertilizer | $7.0M |
| Mushrooms | Fresh Food | $4.8M |
| Polydopamine | Advanced Materials | $4.5M |
| Mushroom Chitosan | Vegan Source | $4.2M |
| Nanocellulose | Coatings | $4.0M |
| AMPs | Pharma | $3.5M |
| Cordycepin | Nutraceutical | $2.0M |
| Inulin | Pharma R&D (Future Pipeline) | — |
Phase 1 Core Product Portfolio
High-value fractionation of 48,000 MT/year brewery waste
Pure Melanin
Semiconductor Grade
| Specification | Value |
|---|---|
| Pricing | $250,000/kg |
| Daily Output | 315 grams |
Applications
| Application Areas |
|---|
| Bioelectronics |
| Radiation Shielding |
Annual Revenue
| Revenue |
|---|
| $27.56M |
Green Chitosan
Pharmaceutical Grade
| Specification | Value |
|---|---|
| Pricing | $75/kg |
| Daily Output | 580 kg |
Applications
| Application Areas |
|---|
| Pharma |
| Agri-Coatings |
Annual Revenue
| Revenue |
|---|
| $15.23M |
Protein Meal
Defatted Insect Meal
| Specification | Value |
|---|---|
| Pricing | $1.50/kg |
| Daily Output | 10,422 kg |
Applications
| Application Areas |
|---|
| Aquaculture |
| Pet Food |
Annual Revenue
| Revenue |
|---|
| $5.47M |
Insect Oil
Lauric Acid Rich
| Specification | Value |
|---|---|
| Pricing | $2.50/L |
| Daily Output | 6,676 Liters |
Applications
| Application Areas |
|---|
| Biodiesel |
| Cosmetics |
Annual Revenue
| Revenue |
|---|
| $5.84M |
Phase 2 Expansion Products
Strategic Roadmap
Expanding into 8 additional high-value streams to create a complete regenerative ecosystem.
Launching Year 3
Biochar Fertilizer
Premium regenerative agriculture product.
350k bags/year.
| Projected Revenue |
|---|
| $7.0M |
Mushroom Food
Fresh Oyster/Shiitake to food companies.
50 MT/month.
| Projected Revenue |
|---|
| $4.8M |
Polydopamine
Advanced melanin-derivative material for medical devices.
| Projected Revenue |
|---|
| $4.5M |
Vegan Chitosan
Fungal origin for vegan supplements & pharma markets.
| Projected Revenue |
|---|
| $4.2M |
Nanocellulose
Derived from Hemp. 50k kg/year output for composites.
| Projected Revenue |
|---|
| $4.0M |
AMPs
Antimicrobial peptides for pharmaceutical R&D partnerships.
| Projected Revenue |
|---|
| $3.5M |
Cordycepin
High-value nutraceutical extracted from Cordyceps fungi.
| Projected Revenue |
|---|
| $2.0M |
Lab Services
Contract testing utilizing analytical lab capacity.
| Projected Revenue |
|---|
| $0.5M |
Melanin: The Ultra-High-Value Driver
Phase 1 Core Products
Annual Revenue (Year 5): $27.56M
Bio-Electronic Grade
99.9% Pure Eumelanin derived from BSF biomass. A premium organic semiconductor for next-generation electronics.
Market Specifications
| Parameter | Value |
|---|---|
| Market Price | $250,000/kg |
| Daily Output | 315 g |
| Purity | 99.9% |
Performance vs. Traditional Materials
Thermal Stability
| Property | Performance |
|---|---|
| Decomposition Temperature | 1500°C |
| Conventional Material | Organic Polymers (~350°C) |
Melanin maintains structural integrity in extreme aerospace environments where traditional organics fail.
Photothermal Conversion Efficiency
| Property | Value |
|---|---|
| Conversion Efficiency | 90% |
| Conventional Materials | Typical Inorganic (<50%) |
Key Applications
| Application | Primary Use |
|---|---|
| Bioelectronics | Biodegradable batteries & sensors |
| Radiation Shielding | Aerospace coating applications |
| Medical Devices | Biocompatible implants |
Revenue Contribution
| Metric | Value |
|---|---|
| Share of Total Year 5 Revenue | 32.6% |
Dual-Source Chitosan Strategy
Strategic Market Segmentation
Total Revenue Potential: $19.43M/year
BSF Green Chitosan
The Performance Standard
Production & Pricing
| Parameter | Value |
|---|---|
| Daily Output | 580 kg |
| Price Point | $75/kg |
Technical Advantage
>90% Deacetylation
High charge density for maximum efficacy.
Annual Revenue
| Revenue |
|---|
| $15.23M |
Target Markets
| Market | Primary Applications |
|---|---|
| Agriculture | Seed coatings, pathogen control |
| Pharmaceuticals | Drug delivery, wound care |
Vegan Chitosan
The Ethical Premium
Production & Pricing
| Parameter | Value |
|---|---|
| Daily Output | 200 kg |
| Price Point | $60/kg |
Market Advantage
100% Plant-Based
Allergen-free, Kosher & Halal compliant.
Annual Revenue
| Revenue |
|---|
| $4.20M |
Target Markets
| Market | Primary Applications |
|---|---|
| Supplements | Weight loss, Cholesterol |
| Personal Care | Clean beauty, Haircare |
Regenerative Agriculture Building Blocks
Phase 2 Ecosystem | Circular Economy
Closed-Loop System
Smart Composite Coatings
Technology
| Component | Description |
|---|---|
| Technology | Chitosan + Nanocellulose Matrix |
Performance
Rain-fast, slow-release electrostatic delivery.
Synergistic Circular Platform
The integrated platform connects regenerative agriculture, biomass utilization, and advanced biomaterials through a closed-loop production ecosystem.
Hemp Cultivation
| Parameter | Value |
|---|---|
| Scale | 100 Acres (Phase 1/2) |
Purpose
Source for Nanocellulose & Biochar feedstock.
Inoculated Biochar
| Parameter | Value |
|---|---|
| Output | 350,000 Bags/Year |
Description
Pyrolyzed biomass + beneficial microbial inoculation.
Environmental Impact
Carbon Negative
10,000+ tonnes CO₂ sequestered via hemp & biochar burial.
Chemical Replacement
Replaces synthetic pesticides with biological chitosan solutions.
Soil Regeneration
Restores depleted soils and improves water retention.
Local Economic Impact
| Metric | Value |
|---|---|
| Green Jobs | 42 |
| Value Added | 20× |
Creating a new high-value biotech sector in Guatemala.
Investment & Phased Deployment
Strategic Roadmap
Total Project Investment: $14.12M
Phase 1: Validation
Deployed Years 1–2 • Proving Core Technology
Phase 1 CAPEX Items
| CAPEX Item | Cost |
|---|---|
| Analytical Laboratory | $1.52M |
| Rearing Infrastructure | $1.45M |
| Processing Equipment | $0.98M |
| Other / Contingency | $2.50M |
| Total Phase 1 CAPEX | $6.45M |
Phase Budget: $9.45M
Phase 2: Expansion
Deployed Year 3 • Scaling & Diversification
Phase 2 CAPEX Items
| CAPEX Item | Cost |
|---|---|
| Nanocellulose Factory | $1.30M |
| Mushroom Facility | $0.95M |
| Hemp Equipment (100ac) | $0.85M |
| Biochar / Advanced Bio | $1.15M |
| Total Phase 2 CAPEX | $4.68M |
Phase Budget: $4.68M
5-Year Execution Timeline
Year 1: Foundation
50% Capacity Utilization
- Commission Phase 1 facility
- Validate core BSF processes
- Establish brewery partnership
Projected Revenue: $27.1M
Year 2: Optimization
65% Capacity Utilization
- Achieve pharmaceutical grade specs
- Optimize extraction yields
- Prepare Phase 2 engineering
Projected Revenue: $35.2M
Year 3: Phase 2 Launch
80% Phase 1 | 50% Phase 2
- Deploy $4.68M Phase 2 CAPEX
- Launch 8 expansion products
Revenue Jump: $58.5M
Year 4: Scaling
90% Phase 1 | 75% Phase 2
Projected Revenue: $71.6M
Year 5: Full Integration
100% Phase 1 | 100% Phase 2
- Fully integrated biorefinery operations
- All revenue streams operational
Projected Revenue: $81.4M
Phase 2 CAPEX Breakdown
Strategic Expansion Investment
Total Expansion Capital: $4.675M
Capital Allocation Detail
Deployed Year 3
| Investment Category | Description | Amount | Allocation |
|---|---|---|---|
| Nanocellulose Factory | Processing equipment & bioreactors | $1.30M | 27.8% |
| Hemp Cultivation | Harvesting machinery (100 acres) | $850K | 18.2% |
| Mushroom Facility | Growing chambers expansion | $720K | 15.4% |
| Polydopamine / AMPs | Specialized extraction units | $650K | 13.9% |
| Biochar Systems | Pyrolysis kilns & inoculation | $580K | 12.4% |
| Analytical Lab | Phase 2 upgrades (ICP-MS, SEM) | $575K | 12.3% |
Strategic Efficiency
Phase 2 triples production capacity and adds 7 revenue streams with only 47% additional CAPEX compared to Phase 1.
Key Advantage
Shared Infrastructure Leverage
Investment Priorities
Advanced Materials (28%)
Largest allocation to Nanocellulose reflects high-margin coating strategy.
Regenerative Ag (31%)
Combined Hemp + Biochar investment secures carbon credit revenue.
Pharma Pipeline (26%)
Lab upgrades + extraction units enable Inulin/AMP development.
5-Year Integrated Financial Projections
Phase 1 Validation to Full Phase 2 Expansion
Cumulative Revenue: $254.75M
Cumulative EBITDA: $202.45M
Pro Forma Statement
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Capacity Utilization | 50% | 65% | Phase 2 Launch | 90% | 100% |
| Total Revenue | $27.05M | $34.08M | $47.41M | $64.81M | $81.40M |
| COGS (~13%) | ($3.52M) | ($4.43M) | ($6.16M) | ($8.43M) | ($10.58M) |
| Gross Profit | $23.53M | $29.65M | $41.25M | $56.38M | $70.82M |
| OPEX | ($3.00M) | ($3.00M) | ($4.40M) | ($4.40M) | ($4.40M) |
| EBITDA | $20.53M | $26.65M | $36.85M | $51.99M | $66.42M |
Revenue Growth & Composition
Revenue by Year
| Year | Phase 1 | Phase 2 |
|---|---|---|
| Year 1 | $27M | — |
| Year 2 | $34M | — |
| Year 3 | $41M | $7M |
| Year 4 | $48M | $17M |
| Year 5 | $54M | $27M |
EBITDA Margin Trend
| Year | Margin |
|---|---|
| Year 1 | 75.9% |
| Year 2 | 78.2% |
| Year 3 | 77.7% |
| Year 4 | 80.2% |
| Year 5 | 81.6% |
5-Year Cumulative EBITDA
| Metric | Value |
|---|---|
| EBITDA | $202.45M |
| Average Margin | 79.5% |
5-Year ROI
| Metric | Value |
|---|---|
| Return on Investment | 1,334% |
Facility Specifications & Operations
Operational Infrastructure
Total Footprint: 30,000 sq ft
Location: Guatemala City
Rearing Capacity
Tray Configuration
| Metric | Value |
|---|---|
| Total Tray Configuration | 27,180 Units |
| Small Trays | 14,670 |
| Large Trays | 12,510 |
Production Stages
- Small Trays — Neonate Stage
- Large Trays — Finishing Stage
Climate Control
| Parameter | Target |
|---|---|
| Temperature | 28°C ±1°C |
| Relative Humidity | 65% ±5% |
Key Equipment Stack
Analytical Laboratory
| Equipment | Purpose |
|---|---|
| HPLC, LC-MS/MS, GC-MS | Pharmaceutical-grade analytical testing |
Functions
- QA/QC
- R&D
Investment: $1.52M
Microwave Dispersion
| Equipment | Purpose |
|---|---|
| High-efficiency extraction unit | Enhances chitin recovery & yield |
Wet Processing
| Equipment | Purpose |
|---|---|
| Enzymatic hydrolysis reactors | Primary extraction process |
Drying Systems
| Equipment | Purpose |
|---|---|
| Spray drying & lyophilization | Final product stabilization |
Human Capital
Phase 1 Team
| Department | FTE |
|---|---|
| Operations, Laboratory & Rearing | 28 FTE |
Phase 2 Team
| Department | FTE |
|---|---|
| Expansion & Ag Tech | 42 FTE |
Cost Advantage
Guatemala labor cost is approximately 30% of the U.S. equivalent for a skilled biotechnology workforce.
Daily Throughput Target
| Input | Output |
|---|---|
| MT Waste In | 45.7 MT |
| MT Product Out | 11.3 MT |
Competitive Advantages
Strategic Moat
Market Leadership
Diversified Revenue
| Metric | Value |
|---|---|
| Revenue Streams | 11 |
Business Coverage
- Spanning 6 industries
- No product contributes more than 33% of total revenue
Pharma-Grade Specs
| Metric | Value |
|---|---|
| Analytical Laboratory Investment | $1.52M |
Capability
HPLC/LC-MS analytics ensure strict pharmaceutical purity standards.
Dual-Source Strategy
| Metric | Value |
|---|---|
| Market Coverage | 100% |
Advantage
Insect + Vegan Chitosan covers all major market segments.
Proven Technology
| Metric | Value |
|---|---|
| Extraction Yield | 53.5% |
Performance
Validated extraction efficiency with >90% deacetylation.
Guatemala Advantage vs. Global Competitors
Annual Labor Costs (28 FTE)
| Region | Annual Cost |
|---|---|
| Guatemala | $0.85M |
| EU Average | $2.40M |
| US Average | $2.90M |
Savings: 70%
Annual Production COGS
| Region | Annual Cost |
|---|---|
| Guatemala | $3.52M |
| EU Competitor | $4.90M |
| US Competitor | $5.80M |
Savings: 40%
Shipping Time to U.S. Markets
| Origin | Transit Time |
|---|---|
| Guatemala (Air) | 4 Hours |
| China (Air) | 20 Hours |
| India (Air) | 24+ Hours |
Advantage: 85% Faster
Time Zone Difference (U.S. EST)
| Location | Difference |
|---|---|
| Guatemala | 0 Hours (Same Timezone) |
| Western Europe | +6 Hours |
| Asia (China/India) | +12–15 Hours |
Risk Mitigation Matrix
Strategic Framework
| Risk Category | Mitigation Strategy | Impact Level |
|---|---|---|
| Market Risk | Diversified revenue across 11 streams spanning 6 industries. No single product contributes more than 33% of total revenue. | LOW |
| Technical Risk | Proven 53.45% extraction efficiency, $1.52M analytical laboratory, validated extraction process, and cGMP-compatible production protocols. | LOW |
| Feedstock Risk | Long-term brewery partnership securing 48,000 MT/year of feedstock. No competing industrial use for raw material. | VERY LOW |
| Pricing Risk (Melanin) | Conservative pricing at $250,000/kg compared with an estimated $400,000/kg market value. Eleven additional revenue streams reduce price volatility. | LOW |
| Operational Risk | Pharmaceutical-grade quality control, skilled Guatemala workforce, and approximately 70% labor cost advantage over U.S. operations. | LOW |
| Regulatory Risk | FDA and USDA engagement, Chitosan GRAS status, and established regulatory pathways for mushroom-derived food products. | MEDIUM |
| Competition Risk | First-mover advantage with an estimated 3–5 year technology lead, proprietary green extraction process, and high barriers to entry. | LOW |
| ESG Risk | Carbon-negative operations, verified waste diversion, and sustainability certification initiatives supporting environmental compliance. | LOW |
Remediation and Regeneration – Doing the Right Thing is Finally Profitable
Strategic Vision
Practical Solutions for Sustainable Food Production
Our biorefinery delivers a Remediation Trifecta, addressing soil health, chemical elimination, and water protection through nature-based biotechnology.
Biopolymer Coatings
Chitosan–Nanocellulose
Key Benefits
- Provides 90-day pathogen protection
- Eliminates synthetic pesticides
- Extends post-harvest shelf life
Soil Restoration
Inoculated Biochar
Environmental Benefits
- Sequesters 10,000+ tons CO₂/year
- Remediates heavy metals
- Improves nutrient retention by 40%
Clean Water
Systemic Protection
Water Protection Benefits
- Ensures zero toxic runoff
- Closed-loop waste management
- Protects freshwater ecosystems
Investment & Value Creation Path
| Milestone | Timeline | Objective |
|---|---|---|
| Today | Seed & Series A | $14.12M |
| Year 3 | Phase 2 Launch | Scale Operations |
| Year 4 | Impact | Heal 1M+ Acres |
| Year 5 | Strategic IPO | Exit |
5-Year Timeline
Target Exit Valuation
$1.2 Billion IPO
Investment Multiple
12× EBITDA Multiple
Join the Platform
Target Impact
- Heal 1M+ acres
- Commercial regenerative agriculture deployment
- Global remediation platform
Contact
Investment Status
Series A Open